As we observed in prostate cancer cells (20,25), blocking of HER/HER2 function by lapatinib or NF-κB activity by bortezomib significantly reduces sPLA2-IIa expression in H1975 cells (Fig. 2A). Here, ERBB2 is linked to Familial prostate cancer.